Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy Against Highly Resistant BCR-ABL1 Mutants

BCR-ABL1 point mutation-mediated resistance to tyrosine kinase inhibitor (TKI) therapy in Philadelphia chromosome-positive (Ph(+)) leukemia is effectively managed with several approved drugs, including ponatinib for BCR-ABL1(T315I)-mutant disease. However, therapy options are limited for patients wi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Cell
Main Authors: Eide, Christopher A., Zabriskie, Matthew S., Savage Stevens, Samantha L., Antelope, Orlando, Vellore, Nadeem A., Than, Hein, Schultz, Anna Reister, Clair, Phillip, Bowler, Amber D., Pomicter, Anthony D., Yan, Dongqing, Senina, Anna V., Qiang, Wang, Kelley, Todd W., Szankasi, Philippe, Heinrich, Michael C., Tyner, Jeffrey W., Rea, Delphine, Cayuela, Jean-Michel, Kim, Dong-Wook, Tognon, Cristina E., O’Hare, Thomas, Druker, Brian J., Deininger, Michael W.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6893878/
https://ncbi.nlm.nih.gov/pubmed/31543464
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2019.08.004
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados